Merck & Co., Inc.

NYSE MRK

Merck & Co., Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024: USD -3.42 B

Merck & Co., Inc. Capital Expenditure is USD -3.42 B for the Trailing 12 Months (TTM) ending September 30, 2024, a 14.89% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Merck & Co., Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -4.02 B, a 9.53% change year over year.
Merck & Co., Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -4.45 B, a 6.46% change year over year.
Merck & Co., Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -4.75 B, a -10.38% change year over year.
Merck & Co., Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -4.31 B, a -31.91% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NYSE: MRK

Merck & Co., Inc.

CEO	Mr. Robert M. Davis J.D.
IPO Date	Jan. 13, 1978
Location	United States
Headquarters	2000 Galloping Hill Road
Employees	70,000
Sector	Health Care
Industries Pharmaceuticals Hospitals & Clinics

Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Key trends

Past 5 years